Coya Therapeutics company info

What does Coya Therapeutics do?
Coya Therapeutics (NASDAQ:COYA) focuses on developing innovative therapies aimed at combating a wide range of autoimmune, neurodegenerative, and aging-related diseases. By harnessing the power of regulatory T cells (Tregs) and leveraging advanced biotechnological processes, Coya Therapeutics aims to pave new pathways in the treatment of conditions like ALS (Amyotrophic Lateral Sclerosis), Alzheimer’s disease, and systemic lupus erythematosus (SLE). Central to their mission is the commitment to advancing clinical research, with several key projects in various stages of development aimed at unlocking the therapeutic potential of Tregs. Their objectives include not only advancing the science behind autoimmune and neurodegenerative disease treatments but also improving the quality of life for patients suffering from these challenging conditions.
Coya Therapeutics  company media
Company Snapshot

Is Coya Therapeutics a public or private company?

key
Ownership
Public

How many people does Coya Therapeutics employ?

people
Employees
8

What sector is Coya Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Coya Therapeutics ?

location pin
Head Office
Houston, United States

What year was Coya Therapeutics founded?

founded flag
Year Founded
2020
What does Coya Therapeutics specialise in?
/Cell Therapies /Cancer Treatment /Autoimmune Diseases /Personalized Immunotherapies /Preclinical Platform /Healthcare Solutions

What are the products and/or services of Coya Therapeutics ?

Overview of Coya Therapeutics offerings
Development of therapeutic treatments focused on neurodegenerative diseases such as ALS and Alzheimer's.
Research on anti-inflammatory therapeutics for autoimmune disorders.
Innovative approaches to enhancing the bioavailability of treatments for better patient outcomes.
Collaborations with academic institutions for advanced research in neurology and immunology.
Engagement in clinical trials to validate the efficacy and safety of new drugs and therapies.
Leveraging proprietary technology platforms to discover novel therapeutic targets.

Who is in the executive team of Coya Therapeutics ?

Coya Therapeutics leadership team
  • Dr. Howard  Berman Ph.D.
    Dr. Howard Berman Ph.D.
    Chairman & CEO
  • Dr. Fred  Grossman D.O., FAPA
    Dr. Fred Grossman D.O., FAPA
    President & Chief Medical Officer
  • Mr. David S. Snyder
    Mr. David S. Snyder
    CFO & COO
  • Dr. Gregory  MacMichael Ph.D.
    Dr. Gregory MacMichael Ph.D.
    Chief Technical Officer
  • Dr. Michelle  Frazier Ph.D.
    Dr. Michelle Frazier Ph.D.
    Senior Vice President of Regulatory Affairs
  • Mr. Aaron  Thome Ph.D.
    Mr. Aaron Thome Ph.D.
    Head of Neuroinflammation Platform
  • Dr. Arun  Swaminathan Ph.D.
    Dr. Arun Swaminathan Ph.D.
    Chief Business Development Officer